Morgan Stanley Forecasts Strong Price Appreciation for Envista (NYSE:NVST) Stock

Envista (NYSE:NVST) had its price objective upped by stock analysts at Morgan Stanley from $19.00 to $20.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 2.82% from the stock’s current price.

A number of other brokerages have also recently issued reports on NVST. Piper Sandler boosted their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday. Jefferies Financial Group boosted their price target on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Robert W. Baird lifted their target price on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Stifel Nicolaus raised their price target on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Envista in a research report on Thursday. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $20.13.

Envista Price Performance

Shares of NYSE NVST opened at $20.58 on Thursday. The stock has a market capitalization of $3.54 billion, a PE ratio of -2.65, a P/E/G ratio of 1.82 and a beta of 1.34. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $24.79. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The business has a fifty day moving average price of $19.97 and a two-hundred day moving average price of $19.10.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. As a group, equities analysts predict that Envista will post 0.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Several large investors have recently added to or reduced their stakes in NVST. US Bancorp DE raised its holdings in shares of Envista by 340.9% in the fourth quarter. US Bancorp DE now owns 21,919 shares of the company’s stock valued at $423,000 after purchasing an additional 16,948 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Envista in the 4th quarter valued at about $358,000. Amalgamated Bank increased its stake in Envista by 0.7% in the 4th quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock valued at $1,551,000 after buying an additional 523 shares during the last quarter. Hudson Edge Investment Partners Inc. lifted its position in shares of Envista by 4.8% during the 4th quarter. Hudson Edge Investment Partners Inc. now owns 24,931 shares of the company’s stock worth $481,000 after buying an additional 1,150 shares in the last quarter. Finally, Paradice Investment Management LLC boosted its stake in shares of Envista by 3.8% in the 4th quarter. Paradice Investment Management LLC now owns 1,652,332 shares of the company’s stock worth $31,873,000 after buying an additional 61,139 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.